Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bio Key International (BKYI) EBITDA (2016 - 2025)

Bio Key International (BKYI) has disclosed EBITDA for 16 consecutive years, with -$1.0 million as the latest value for Q3 2025.

  • Quarterly EBITDA fell 60.05% to -$1.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$4.3 million through Sep 2025, up 15.93% year-over-year, with the annual reading at -$4.3 million for FY2024, 48.23% up from the prior year.
  • EBITDA hit -$1.0 million in Q3 2025 for Bio Key International, up from -$1.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$572560.0 in Q1 2024 to a low of -$6.8 million in Q4 2022.
  • Historically, EBITDA has averaged -$1.7 million across 5 years, with a median of -$1.4 million in 2024.
  • Biggest five-year swings in EBITDA: tumbled 478.25% in 2021 and later soared 67.15% in 2023.
  • Year by year, EBITDA stood at -$2.0 million in 2021, then tumbled by 240.23% to -$6.8 million in 2022, then skyrocketed by 67.15% to -$2.2 million in 2023, then soared by 36.91% to -$1.4 million in 2024, then rose by 26.32% to -$1.0 million in 2025.
  • Business Quant data shows EBITDA for BKYI at -$1.0 million in Q3 2025, -$1.1 million in Q2 2025, and -$729742.0 in Q1 2025.